BioSpace News Archive

Transparency Market Research has recently published a new research report that talks about the overall landscape of the global empty capsules market.

Evasc Neurovascular, a pioneer in the development of disruptive endovascular treatments for cerebral aneurysms, announced the enrollment of the first patient in its French eCLIPs™ Safety, Feasibility and Efficacy Study.

Lysogene, a gene therapy platform company targeting central nervous system diseases, announced the termination of its license agreement with Sarepta for LYS-SAF302, a phase 2/3 asset for the treatment of mucopolysaccharidosis Type IIIA, effective as of July 11, 2022.

The Baszucki Brain Research Fund and the Milken Institute’s Center for Strategic Philanthropy are pleased to announce that 45 scientists worldwide will receive funding to advance research for bipolar disorder.

ADVANZ PHARMA Corp. Limited and Allecra Therapeutics announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway.

Electromedical Technologies, Inc., a pioneer in the development and manufacturing of bioelectronic devices, is pleased to issue the following Annual Letter to Shareholders from the Company’s Chief Executive Officer:

Angelini Pharma, an international pharmaceutical company which is part of the privately-owned Angelini Industries, has appointed Rafal Kaminski as its new Chief Scientific Officer.

ONL Therapeutics, Inc. today announced it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million.

Salarius Pharmaceuticals, Inc. today announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio.

PacBio welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the company’s Americas region.